Meeting
2021 Genitourinary Cancers Symposium
Significance of targeting the antiapoptotic pathway in castration-sensitive prostate cancer.
Authors
Goutam Chakraborty
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Goutam Chakraborty , Rahim Hirani , Subhiksha Nandakumar , Teja Muralidhar Kalidindi , Deborah Fidele , Sai Harisha Rajanala , Ying Zhang Mazzu , Yuki Yoshikawa , Lina E. Jehane , Gwo-Shu Mary Lee , Elisa de Stanchina , Adam G. Sowalsky , Michael J. Morris , Heiko Schöder , Naga Vara Kishore Pillarsetty , Lorelei A Mucci , Daniel Costin Danila , Philip W. Kantoff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Localized Disease
Track
Prostate Cancer - Localized
Sub Track
Translational Research
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 250)
DOI
10.1200/JCO.2021.39.6_suppl.250
Abstract #
250
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
ProstACT GLOBAL: A phase 3 study of best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
First Author: Charlotte Hawkins
Poster
2023 ASCO Annual Meeting
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide.
First Author: Siyuan S Guo
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
First Author: Alyssa Liang
Poster
2016 Genitourinary Cancers Symposium
Identification of a predictive factor of metastatic castration-resistant prostate cancer patients’ response to alternative antiandrogen therapy with flutamide.
First Author: Masato Yasui